Curriculum Viate

RANGAPRASAD SARANGARAJAN, PH.D.

CHIEF SCIENTIFIC OFFICER | SENIOR VICE PRESIDENT OF RESEARCH & DEVELOPMENT 

Contact Information: rangaprasad.sarangarajan@gmail.com

www.linkedin.com/in/rangaprasad-sarangarajan-b82b29

PASSION FOR DELIVERING ACTIONABLE VALUE APPLICATIONS FROM BIOLOGICAL MODELS TO HUMAN HEALTH USING COMBINATION OF BIOLOGY, TECHNOLOGY & ANALYTICS 

A senior executive with a successful career in life sciences research, diagnostics, and clinical development. My expertise is specializing in uncovering novel biological mechanisms by creating or from existing multi-omic data platforms (artificial intelligence & machine learning outputs) with clear & unique commercial applications. My experience lies in combining scientific innovation with focused business fundamentals to drive innovation & asset pipelines to create value.

Focused on creating and executing scientific strategies, I’ve led cross-functional teams to building biology data constructs that merge biology, technology, and AI/ML analytics for phenotype driven biomarker based target discovery with seamless translation into drug, diagnostic, and clinical development. I have been involved in successfully securing financing rounds, manage multi-million-dollar budgets and forged strategic partnerships across academia, industry, and regulatory bodies.

Skilled in turning scientific insights into commercially viable solutions, I’ve advanced proprietary solutions in the management of disease and focused on health, wellness, and precision medicine. My goal is to apply my expertise in science, strategy, and leadership to drive growth and innovation within an ambitious organization. 

EXPERTISE

Scientific Strategy ▪ Drug Discovery ▪ Metabolomics ▪ AI/ML in Research ▪ Biomarker Discovery ▪ Clinical Trial Design ▪ R&D Development ▪ Regulatory Compliance ▪ Translational Research ▪ Precision Medicine ▪ Biotechnology ▪ Budget Management ▪ Team Leadership ▪ Patent Filing ▪ Strategic Partnerships

PROFESSIONAL EXPERIENCE 

Metabolon, Inc.

Metabolon Inc. specializes in precision health and diagnostics using advanced metabolomics technology. Chief Scientific Officer 

▪     2021 to 2024

Developed and executed the scientific strategy for the broader use of metabolomics across multiple scientific areas and market segments. Managed the core R&D technology and data generation processes. Led basic and applied science teams in translating scientific discoveries to support marketing and sales. Directed external collaborations and contributed to scientific publications. Collaborated with leadership on business development and financing. Led cross-functional science and technology teams for new product development

Key Accomplishments: 

▪ Develop & execute scientific strategy on demonstrating the value of metabolomic in basic science, clinical translation, clinical development & health/wellness applications 

▪ Discovered a panel of novel biomarkers, identified target, leading to the validation of small molecule therapeutics 

▪ Launched three new products within a year and a half, accelerating the company's product pipeline

▪ Active contribution in successful round of financing by developing compelling business packages in collaboration with the leadership team

▪ Advanced the field of biomarker discovery and personalized medicine in the basic sciences & population health 

BPGbio, Inc. (fka BERG, LLC)

Clinical Stage Biotech with Multi-omic Molecular Platform for Discovery Biology & Asset Generation

Chief Scientific Officer & SVP Clinical & Translational Sciences

▪ 2010 to 2021 

Provided overall scientific leadership within the organization, overseeing the product pipeline of therapeutics in oncology, neurology, and cardiovascular metabolic disease. Managed multi-million-dollar R&D and clinical budgets, ensuring strategic collaborations with academic, foundation, and industry partners. Led multifunctional teams to innovate and stay at the forefront of systems biology/engineering, pan-omics, data sciences, and analytics. Directed the discovery, clinical translation, and regulatory processes for multiple therapeutic programs from early to mid-stage development. Drove corporate growth and innovation by translating strategic goals into actionable plans and participating in equity and capital market discussions

Key Accomplishments: 

▪ Third member of founding team; lead & management building of a comprehensive R&D infrastructure bottom-up into fully integrated biology, multi-omic molecular profiling, assay technology & AI/ML analytics infrastructure for data driven biology discovery, target identification & drug development

▪Lead & manage discovery & validation of insilico biology outputs; responsible for building pipeline of novel assets in oncology, neurology, cardiovascular & metabolic disease and rare disease 

▪ Led the discovery and validation of large molecules in cardiovascular metabolic disease, including the development of PEGylated therapeutics and successful preclinical validation

▪ Compiled and submitted two Orphan Drug Designation packages, resulting in the granting of Orphan Drug Status

▪ Led a multi-functional team for clinical development in oncology, achieving successful EOP1 meetings for Phase 2/3 strategies for topical small molecules targeting chemotherapy-related side effects and rare diseases

▪ Directed efforts in formulation development and technology scale-up for intravenous small molecule cancer treatments, leading to successful GMP suite implementation and production of GMP products

▪ Played a pivotal role in the development of clinical protocols and multi-omic pharmacodynamic profiling, contributing to late-stage development of several programs 

▪ Collaborated with Oak Ridge National Laboratory to streamline in silico workflows for rapid target validation and drug discovery, enhancing the pipeline across multiple disease indications 

▪ Secured multiple patents by collaborating with outside counsel and providing comprehensive data for effective prosecution, resulting in the granting of national and international patents

EARLY CAREER

Associate Professor of Pharmacology & Toxicology 

▪     Massachusetts College of Pharmacy & Health Science 

▪  Established a Pioneering Pharmacy Program: Served as a founding team member at Massachusetts College of Pharmacy, playing a key role in developing a fully accredited CPE pharmacy school with an innovative accelerator program and advanced online instruction capabilities 

▪ Holistic Approach to Pharmacology and Toxicology: Leveraged classical training in pharmacology and toxicology, combined with advanced molecular biology and genetics, to approach scientific questions with a comprehensive understanding of biological systems, informing both teaching and research

▪ Innovative and Strategic Contributions: Known for identifying novel insights and translating scientific discoveries into valuable applications, significantly advancing research and development at Berg and Metabolon 

Post-doctoral Research Associate 

▪ Department of Dermatology, University of Cincinnati College of Medicine Post-doctoral Fellow ▪ Division of Hematology/Oncology, Children’s Hospital Research Foundation, Children’s Hospital Medical Center 

EDUCATIONAL BACKGROUND 

Ph.D. in Pharmaceutical Sciences – University of Cincinnati College of Pharmacy B.S. in Pharmacy – Maharaja Sayajirao University